Other Information
−Removed: None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K.
−Removed: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended March 31, 2024.
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended June 30, 2024 , as such terms are defined under Item 408 (a) of Regulation S-K.
+Added: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended June 30, 2024 .
Exhibit Number
3 unchanged sentences
Exhibit 1.1 to the Current Report on Form 8-K, filed on April 19, 2024
−Removed: Exhibit Number
−Removed: Incorporation by Reference
Form of Underwriter’s Warrant between NRx Pharmaceuticals, Inc.
8 unchanged sentences
Interactive data files pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL:
−Removed: (i) Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023;
−Removed: (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 ;
−Removed: (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three months ended March 31, 2024 and 2023;
−Removed: (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023;
+Added: (i) Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023;
+Added: (ii) Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 ;
+Added: (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and six months ended June 30, 2024 and 2023;
+Added: (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023;
and (v) Notes to Unaudited Financial Statements.
6 unchanged sentences
NRX PHARMACEUTICALS, INC.
+Added: August 14, 2024
/s/ Richard Narido
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.